INT136503

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 2005
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 46
Total Number 46
Disease Relevance 43.10
Pain Relevance 1.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) plasma membrane (KDR)
nucleus (KDR) cytoplasm (KDR)
Anatomy Link Frequency
thyroid 2
stroma 1
plasma 1
platelet 1
KDR (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 32 93.16 High High
palliative 31 91.88 High High
fibrosis 34 88.56 High High
Inflammation 38 87.04 High High
cva 53 83.92 Quite High
nud 6 82.00 Quite High
Pain 59 74.08 Quite High
antagonist 19 73.64 Quite High
pruritus 3 70.56 Quite High
cytokine 75 68.48 Quite High
Disease Link Frequency Relevance Heat
Cancer 1873 99.84 Very High Very High Very High
Myelodysplastic Syndromes 55 99.84 Very High Very High Very High
Disease Progression 61 99.80 Very High Very High Very High
Solid Tumor 186 99.50 Very High Very High Very High
Fibromyalgia 23 99.40 Very High Very High Very High
Reprotox - General 1 162 99.24 Very High Very High Very High
Myelofibrosis 55 99.00 Very High Very High Very High
Camurati-engelmann Disease 30 98.88 Very High Very High Very High
Myeloproliferative Disorder 65 98.86 Very High Very High Very High
Breast Cancer 459 98.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
SU5416 (Semaxinib) is a small molecule inhibitor of VEGFR-1 and 2, c-kit and Flt3 [70-72].
Negative_regulation (inhibitor) of VEGFR
1) Confidence 0.48 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.83 Pain Relevance 0.17
Cediranib (AZD2171, Recentin®) is a potent inhibitor of both VEGFR-1 and VEGFR-2; it also has activity against c-kit, PDGFR-?
Negative_regulation (inhibitor) of VEGFR
2) Confidence 0.48 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.67 Pain Relevance 0
The analyses were performed on genomic DNA from 178 patients (143 males and 35 females) with solid tumors who received sorafenib (VEGFR2 inhibitor) and/or bevacizumab (anti-VEGF) with or without other agents.
Negative_regulation (inhibitor) of VEGFR2 associated with solid tumor
3) Confidence 0.42 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2913951 Disease Relevance 1.08 Pain Relevance 0
Cediranib (AZD2171, Recentin®) is a potent inhibitor of both VEGFR-1 and VEGFR-2; it also has activity against c-kit, PDGFR-?
Negative_regulation (inhibitor) of VEGFR
4) Confidence 0.35 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.68 Pain Relevance 0
In MPN, VEGF levels were higher compared to controls, wheresas VEGFR-2 levels was reduced in ET but not in PV and PMF [61].


Neg (not) Negative_regulation (reduced) of VEGFR associated with myeloproliferative disorder, myelodysplastic syndromes and myelofibrosis
5) Confidence 0.35 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.71 Pain Relevance 0
Dose and time-dependent reductions of soluble VEGFR-2 were observed, and there was a correlation between cediranib exposure and plasma VEGF levels [82].


Negative_regulation (reductions) of VEGFR in plasma
6) Confidence 0.35 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.32 Pain Relevance 0.03
Inhibition of the VEGFR mRNA has been attempted both with ribozyme (catalytic RNA molecules), which specifically cleave the mRNAs for the primary VEGFRs [108], and antisense VEGF [109].
Negative_regulation (Inhibition) of VEGFR mRNA
7) Confidence 0.33 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.51 Pain Relevance 0
It was considered worthy of further development after demonstrating potent inhibition of VEGFR-2 tyrosine kinase in recombinant enzyme assays as well as additional activity against VEGFR-3, EGFR and RET tyrosine kinases.
Negative_regulation (inhibition) of VEGFR-2
8) Confidence 0.31 Published 2010 Journal Journal of Thyroid Research Section Body Doc Link PMC2956973 Disease Relevance 0.48 Pain Relevance 0
VEGF signaling pathways have been targeted for treatment by the use of anti-VEGF monoclonal antibodies, antibodies binding to VEGFR and VEGFR tyrosine kinase inhibitors.
Negative_regulation (inhibitors) of VEGFR
9) Confidence 0.31 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.63 Pain Relevance 0.03
VEGF signaling pathways have been targeted for treatment by the use of anti-VEGF monoclonal antibodies, antibodies binding to VEGFR and VEGFR tyrosine kinase inhibitors.
Negative_regulation (inhibitors) of VEGFR
10) Confidence 0.31 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.64 Pain Relevance 0.03
Sorafenib is an oral, potent, dual action Raf protein kinase and VEGFR inhibitor with activity against PDGFR and c-Kit as well.
Negative_regulation (inhibitor) of VEGFR
11) Confidence 0.31 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 1.16 Pain Relevance 0
Vatalanib is a pan-VEGFR tyrosine kinase inhibitor with activity against VEGFR-1, VEGFR-2 and VEGFR-3.
Negative_regulation (inhibitor) of VEGFR
12) Confidence 0.31 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.63 Pain Relevance 0.03
A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145.
Negative_regulation (inhibitor) of VEGFR associated with multiple myeloma
13) Confidence 0.26 Published 2006 Journal Invest New Drugs Section Title Doc Link 16791411 Disease Relevance 1.07 Pain Relevance 0.11
The orally administered VEGFR2 inhibitor ZD6474 was generally well tolerated but exhibited little activity in patients with refractory metastatic breast cancer [102].
Negative_regulation (inhibitor) of VEGFR2 associated with advanced or metastatic breast cancer
14) Confidence 0.24 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 1.63 Pain Relevance 0.19
Based on these promising findings, these small molecular inhibitors of VEGFR tyrosine kinase activity are being tested in the breast cancer setting.
Negative_regulation (inhibitors) of VEGFR associated with breast cancer
15) Confidence 0.24 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.54 Pain Relevance 0
SU11248 (sunitinib malate) is an inhibitor of receptor tyrosine kinases for VEGFR1, VEGFR2, PDGFR, c-kit, and Flt-3.
Negative_regulation (inhibitor) of VEGFR2
16) Confidence 0.24 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.69 Pain Relevance 0.03
Vatalanib is a pan-VEGFR tyrosine kinase inhibitor with activity against VEGFR-1, VEGFR-2 and VEGFR-3.
Negative_regulation (inhibitor) of VEGFR-2
17) Confidence 0.22 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.63 Pain Relevance 0.03
The Cancer and Leukemia Group B (CALGB) 8030, a phase III, trial showed disappointing results for OS and was terminated early.96 Sorafenib, a multikinase inhibitor against VEGFR, platelet-derived growth factor receptor, Kit, and Flt-3, was demonstrated to have no activity in combination with gemcitabine in phase II trial,97 although it is being investigated in the second-line setting.98

Secreted protein acid rich in cysteine (SPARC): the stroma as the target

Negative_regulation (inhibitor) of VEGFR in stroma associated with leukemia and cancer
18) Confidence 0.21 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2939765 Disease Relevance 0.76 Pain Relevance 0
All A. gambiae and C. quinquefasciatus were kept for determination of kdr and Ace.1R genotypes.


Negative_regulation (determination) of kdr
19) Confidence 0.20 Published 2005 Journal Malar J Section Body Doc Link PMC1156935 Disease Relevance 0.12 Pain Relevance 0
Based on this hypothesis, we conducted a phase II trial of ZD6474 (Zactima; a VEGFR inhibitor) 100 mg p.o. daily in patients with relapsed multiple myeloma.
Negative_regulation (inhibitor) of VEGFR associated with multiple myeloma
20) Confidence 0.19 Published 2006 Journal Invest New Drugs Section Abstract Doc Link 16791411 Disease Relevance 0.93 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox